



Valiant Laboratories Limited

Registered Office: 104, Udyog Kshetra, Mulund Goregoan Link Road Mulund west, Mumbai City, Mumbai, Maharashtra, India, 400080

Tel: + 022-49712001 / 49717220 /49717221, **Fax:** +91 891 2850004

Contact Person: CS Akshay Gangurde , Company Secretary & Compliance Officer

Email: complianceofficer@valiantlabs.in **Website:** www.valiantlabs.in

Corporate Identity Number: L24299MH2021PLC365904

ENTITLEMENT LETTER FOR THE RIGHTS ISSUE

Dear Shareholder,

ISSUE OF UP TO 1,08,62,500 FULLY PAID-UP EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF OUR COMPANY (THE “RIGHTS EQUITY SHARES”) FOR CASH AT A PRICE OF ₹75/- PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF ₹65/- PER RIGHTS EQUITY SHARE) AGGREGATING UP TO ₹ 8146.88 LAKHS* ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 1 RIGHTS EQUITY SHARES FOR EVERY 4 FULLY PAID-UP EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, THAT IS ON JULY 19, 2025 (THE “ISSUE”). FOR FURTHER DETAILS, SEE “OFFERING INFORMATION” ON PAGE 74 OF THIS LETTER OF OFFER.

** Assuming full subscription*

You are advised to read the disclaimer carefully before reading, accessing or making any other use of the documents

You have been sent this e-mail (including its enclosures) in electronic form in compliance with the provisions of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, SEBI Rights Issue circulars & and other relevant circulars issued by the Securities and Exchange Board of India from time to time. This e-mail does not constitute an offer of, or a solicitation of an offer to purchase, any securities of VALIANT LABORATORIES LIMITED in any jurisdiction where offers or solicitations are not permitted by law. The information in this e-mail is solely intended for distribution to, and use by Eligible Equity Shareholders as of the Record Date i.e, July 19, 2025, who have provided an Indian address to the Company or who are located in jurisdictions where the offer and sale of the Rights Entitlement or Rights Equity Shares is permitted under laws of such jurisdiction and does not result in and may not be construed as, a public offering in such jurisdictions. By accessing this e-mail and its enclosures, you are hereby deemed to represent that you qualify under one of the foregoing criteria. This e-mail and its enclosures should not be reproduced, transmitted or distributed to any other person.

IF YOU ARE NOT PERMITTED TO VIEW THESE DOCUMENTS OR ARE IN ANY DOUBT AS TO WHETHER YOU ARE PERMITTED TO VIEW THESE DOCUMENTS, PLEASE DELETE THIS E-MAIL WITHOUT ACCESSING OR DISTRIBUTING ITS CONTENTS.

With reference to the above subject, given below are the links to your Rights Entitlement Letter and Application Form, to participate in the Rights Issue. Please note that these documents have to be read along with the email disclaimer, the link of which has been provided below. You can access the same by clicking on the links given



Valiant Laboratories Limited

Registered Office: 104, Udyog Kshetra, Mulund Goregoan Link Road Mulund west, Mumbai City, Mumbai, Maharashtra, India, 400080

Tel: + 022-49712001 / 49717220 /49717221, **Fax:** +91 891 2850004

Contact Person: CS Akshay Gangurde , Company Secretary & Compliance Officer

Email: complianceofficer@valiantlabs.in **Website:** www.valiantlabs.in

Corporate Identity Number: L24299MH2021PLC365904

below to view, download and print the same as required.

AMOUNT PAYABLE PER RIGHT EQUITY SHARES*	FACE VALUE (₹)	PREMIUM (₹)	TOTAL (₹)
On the Issue application	10.00	65.00	75.00
Total	10.00	65.00	75.00

*For further details on Payment Schedule, see “Offering Information” on page 74 of the Letter of Offer.

IF YOU ARE NOT PERMITTED TO VIEW THIS LETTER OR ARE IN ANY DOUBT AS TO WHETHER YOU ARE PERMITTED TO VIEW THIS LETTER, PLEASE TREAT THIS LETTER AS SENT FOR INFORMATION PURPOSES ONLY AND SHOULD NOT BE ACTED UPON FOR SUBSCRIPTION TO THE RIGHTS EQUITY SHARES AND SHOULD NOT BE COPIED OR REDISTRIBUTED.

With reference to above, please find below the details of Equity Shares held by you as on Record Date i.e. July 19, 2025, along with your Rights Entitlements

FOLIO NUMBER / DP OR CLIENT ID	NO. OF EQUITY SHARES HELD BY YOU ON RECORD DATE BEING JULY 19, 2025	NO. OF RIGHTS ENTITLEMENT

THIS IS TO INFORM YOU THAT THE CAPTIONED ISSUE OPENS FOR SUBSCRIPTION ON JULY 28, 2025, AND CLOSES FOR SUBSCRIPTION ON AUGUST 08, 2025

Please refer to the FAQs available on the websites of the Company i.e. <https://valiantlabs.in> and the Registrar to the Issue i.e. <https://web.in.mpms.mufg.com/rightsoffers/rightsissues-PlainPaper.aspx> which may be used as guidance for making an Application in the Rights Issue. Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.

Fractional Entitlements

The Equity Shares are being offered on a rights basis to existing Eligible Equity Shareholders in the ratio of 1:4; i.e 1 (One) Equity Shares for every 4 (Four) Equity Shares held as on the Record Date. As per SEBI Rights Issue Circulars, the fractional entitlements are to be ignored. Accordingly, if the shareholding of any of the Eligible Equity Shareholders is less than 4 (Four) Equity Shares or is not in the multiple of 4 (Four) Equity Shares, the fractional entitlements of such Eligible Equity Shareholders shall be ignored by rounding down of their Rights Entitlements. However, the Eligible Equity Shareholders whose fractional entitlements are being ignored, will be given preferential consideration for the Allotment of 1 (One) additional Equity Share if they apply for additional Equity Shares over and above their Rights Entitlements, if any, subject to availability of Equity Shares in this Issue post allocation towards Rights Entitlements applied for.



Valiant Laboratories Limited

Registered Office: 104, Udyog Kshetra, Mulund Goregoan Link Road Mulund west, Mumbai City, Mumbai, Maharashtra, India, 400080

Tel: + 022-49712001 / 49717220 /49717221, **Fax:** +91 891 2850004

Contact Person: CS Akshay Gangurde , Company Secretary & Compliance Officer

Email: complianceofficer@valiantlabs.in **Website:** www.valiantlabs.in

Corporate Identity Number: L24299MH2021PLC365904

Issue Schedule

You are requested to take note of the following schedule of the Issue:

LAST DATE FOR CREDIT OF RIGHTS ENTITLEMENTS	July 21, 2025
ISSUE OPENING DATE	July 28, 2025
LAST DATE FOR ON MARKET RENUNCIATION OF RIGHTS ENTITLEMENTS #	August 05, 2025
ISSUE CLOSING DATE*	August 08, 2025
FINALISATION OF BASIS OF ALLOTMENT (ON OR ABOUT)	August 11, 2025
DATE OF ALLOTMENT (ON OR ABOUT)	August 11, 2025
DATE OF CREDIT (ON OR ABOUT)	August 12, 2025
DATE OF LISTING (ON OR ABOUT)	August 13, 2025

**Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renounees on or prior to the Issue Closing Date.*

Our Board or a duly authorized committee thereof will have the right to extend the Issue period as it may determine from time to time, provided that this Issue will not remain open in excess of 30 (thirty) days from the Issue Opening Date. Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR DISSEMINATION WOULD BE PROHIBITED BY APPLICABLE LAW.

All capitalized terms used and not defined herein shall have the meaning assigned to them in the Letter of Offer dated July 15, 2025, filed with the Stock Exchange, namely BSE and National Stock Exchange of India Limited and the Securities and Exchange Board of India.

Thanking you
Yours faithfully,

For VALIANT LABORATORIES LIMITED

On behalf of Board of Directors

Sd/-

Name: Mr. Santosh Shantilal Vora

Designation: Managing Director

DIN: 07633923